(Q38773033)

6 September 2017

title

The genetics of drug efficacy: opportunities and challenges (English)

1 reference

6 September 2017

2

1 reference

6 September 2017

Chun-Fang Xu

6

0 references

Dawn Waterworth

7

object named as

Dawn M Waterworth

1 reference

6 September 2017

Matthew R Nelson

1

1 reference

6 September 2017

Liling Warren

3

1 reference

6 September 2017

Arlene R Hughes

4

1 reference

6 September 2017

Stephanie L Chissoe

5

1 reference

6 September 2017

language of work or name

1 reference

14 March 2016

1 reference

6 September 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Nature Reviews Genetics

1 reference

6 September 2017

volume

17

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

197-206

1 reference

Drug reactions enzymes, and biochemical genetics

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Pharmacogenomic information in drug labels: European Medicines Agency perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Replication validity of genetic association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Advances in the Pharmacogenomics of Adverse Drug Reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Why most published research findings are false

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Genome-wide association studies for complex traits: consensus, uncertainty and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

An investigation of the false discovery rate and the misinterpretation of p-values

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Genetic cause of hyperglycaemia and response to treatment in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

The NHGRI GWAS Catalog, a curated resource of SNP-trait associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

A randomized trial of genotype-guided dosing of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Genomic architecture of pharmacological efficacy and adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Five years of GWAS discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Current practices for DNA sample collection and storage in the pharmaceutical industry, and potential areas for harmonization: perspective of the I-PWG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Biomarkers and surrogate endpoints in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Towards the identification of imaging biomarkers in schizophrenia, using multivariate pattern classification at a single-subject level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Molecular target class is predictive of in vitro response profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Predicting drug metabolism: experiment and/or computation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Comprehensive analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

High-resolution multipoint linkage-disequilibrium mapping in the context of a human genome sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

A Bayesian method to incorporate hundreds of functional characteristics with association evidence to improve variant prioritization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Integrating functional data to prioritize causal variants in statistical fine-mapping studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Bayesian statistical methods for genetic association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

On the relative sample size required for multiple comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Community consultation and communication for a population-based DNA biobank: the Marshfield clinic personalized medicine research project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Development of a large-scale de-identified DNA biobank to enable personalized medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

The emerging role of electronic medical records in pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

What makes UK Biobank special?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Predicting clopidogrel response using DNA samples linked to an electronic health record.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Characterization of statin dose response in electronic medical records

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

The pharmacogenomics of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

The role of ATM in response to metformin treatment and activation of AMPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Beyond diagnostic accuracy: the clinical utility of diagnostic tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Pharmacogenetics and coumarin dosing--recalibrating expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Hundreds of variants clustered in genomic loci and biological pathways affect human height

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Fine mapping of five loci associated with low-density lipoprotein cholesterol detects variants that double the explained heritability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Validating therapeutic targets through human genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Genetic variants in C5 and poor response to eculizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

To replicate or not to replicate: the case of pharmacogenetic studies: Have pharmacogenomics failed, or do they just need larger-scale evidence and more replication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Statins for the primary prevention of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Testing drug response in the presence of genetic information: sampling issues for clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

The support of human genetic evidence for approved drug indications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

ADME/PK as part of a rational approach to drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Genetic basis of drug metabolism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRG.2016.12

The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26972588

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Targeted blockade of interleukin-8 abrogates its promotion of cervical cancer growth and metastasis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26972588

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRG.2016.12

1 reference

Dimensions Publication ID

6 September 2017

1036651687

0 references

1 reference